ARCA Biopharma Inc (NASDAQ: ABIO) is climbing in the market today, and for good reason. The company announced that its data has been published in a peer-reviewed journal. Of course, the news excited investors, pushing the stock up. Today, we’ll talk about:
- The data publication;
- what we’re seeing from ABIO stock as a result; and
- what we’ll be watching for ahead.
ABIO Is Climbing On A Data Publication
As mentioned above, ARCA is having an incredibly strong start to the trading session this morning after the company announced the publication of its data in a peer-reviewed journal.
In a press release issued early this morning, the company said that a paper titled, “Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphisms” was published. The paper has been published in Genomic and Precision Medicine, a journla of the American Heart Association.
In the release, ABIO said tha tthe lead author on the paper is Duke University cardiologist Kishan S. Parikh and the senior author is Dr. Michael R. Bristow, CEO at the company.
The data surrounded the company’s bucindolol. In a clinical study, the treatment produced a reduction in ACM (all-cause mortality) among heart failure patients.
In the paper, the authors, including Mr. Bristow, CEO at ABIO, had the following to offer as a conclusion:
Beta-blocker dose effects on all-cause mortality risk may be observed for patients with HFrEF with an ADRB1 Arg389Arg genotype. The observed decreased risk compared with the alternative 389Gly carrier genotype may be because of a true reduction in event rates at high/target doses (bucindolol in BEST) or an increase in event rates with lower doses (other beta-blockers in HF-ACTION). These data support guideline recommendations that in HFrEF, beta-blockers should be used at the higher target doses used in all positive phase 3 trials.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves in the market. In the case of ARCA Biopharma, the news proved to be overwhelmingly positive.
After all, the strong data being published in the peer-reviewed journal offers validation for the comapny’s work. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top.
As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:18), ABIO is trading at $0.50 per share after a gain of $0.038 per share or 8.20% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ABIO. In particular, we’re interested in following the story surrounding the company’s continued work to bring the various assets in its pipeline to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!